Maxim Group Lowers Oncolytics Biotech (NASDAQ:ONCY) Price Target to $3.00

Oncolytics Biotech (NASDAQ:ONCY - Free Report) had its target price cut by Maxim Group from $5.00 to $3.00 in a report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

ONCY has been the subject of several other reports. Leede Financial lowered Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday, November 13th. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a report on Monday. Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th. Finally, Royal Bank of Canada decreased their target price on Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research note on Monday. Three equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Oncolytics Biotech currently has an average rating of "Buy" and an average target price of $4.00.

Oncolytics Biotech Trading Up 1.1 %

Oncolytics Biotech stock traded up $0.01 during midday trading on Monday, hitting $0.63. The stock had a trading volume of 69,837 shares, compared to its average volume of 1,287,882. The stock has a market cap of $53.87 million, a P/E ratio of -2.33 and a beta of 1.18. Oncolytics Biotech has a 12 month low of $0.58 and a 12 month high of $1.53. The business has a fifty day moving average price of $0.76 and a 200 day moving average price of $0.92.

Remove Ads

Hedge Funds Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in shares of Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after buying an additional 24,997 shares during the period. National Bank of Canada FI lifted its position in Oncolytics Biotech by 199.6% in the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock worth $60,000 after purchasing an additional 42,955 shares during the period. Virtu Financial LLC acquired a new stake in Oncolytics Biotech in the fourth quarter worth approximately $90,000. Vantage Point Financial LLC acquired a new stake in Oncolytics Biotech in the fourth quarter worth approximately $27,000. Finally, International Assets Investment Management LLC lifted its position in Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after purchasing an additional 26,069 shares during the period. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.